-+ 0.00%
-+ 0.00%
-+ 0.00%

Eton Pharmaceuticals doses first patient in ET-700 Wilson disease pilot trial

PUBT·04/27/2026 10:51:57
Listen to the news
Eton Pharmaceuticals doses first patient in ET-700 Wilson disease pilot trial
  • Eton Pharmaceuticals dosed first participant in pilot clinical study of ET-700, an extended-release zinc acetate candidate for Wilson disease.
  • Topline results have not been presented; readout is expected in second half of 2026.
  • Study aims to show ET-700 can reduce intestinal copper absorption with a simpler dosing regimen versus Galzin or placebo.
  • Positive data would support moving ET-700 into a pivotal clinical study in early 2027.
  • Management expects ET-700 could generate more than $100 million in peak annual US sales if launched.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eton Pharmaceuticals Inc. published the original content used to generate this news brief on April 27, 2026, and is solely responsible for the information contained therein.